Porter Alliance for Innovative Medicines will be equipped with $130m to advance research from Stanford’s Innovative Medicines Accelerator.

Stanford University and investment firm Deerfield Management entered into a collaboration agreement yesterday and launched Porter Alliance for Innovative Medicines with up to $130m in capital. Porter Alliance will look to accelerate translational research, particularly from Stanford’s Innovative Medicines Accelerator, into clinical therapeutics. It is the latest such collaboration that Deerfield has inked over the…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.